Objectives: To make an inventory of indicators that assess antibiotic prescriptions and are linked to specific targets and incentives, at a national level.
Introduction
Most countries in Europe use indicators to monitor antibiotic prescriptions as part of their national antimicrobial stewardship (AMS) programmes. 1 A number of international initiatives have recently attempted to validate indicators to monitor antibiotic prescriptions, such as the DRIVE-AB project and the Transatlantic Taskforce on Antimicrobial Resistance (TATFAR). 2, 3 In the UK, economist Jim O'Neill was commissioned in 2014 to analyse the global problem of rising drug resistance and propose concrete actions to tackle it internationally. One of the Government's objectives following the final 2016 O'Neill Review on Antimicrobial Resistance was to aim at reducing inappropriate antibiotic prescribing by 50%, with the aim of being a world leader in reducing prescribing by 2020. 4, 5 V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. As part of identifying the level of inappropriate prescribing in the UK, the Government wanted to look at approaches taken by other countries. 5 Given the lack of published or easily accessible data on indicators that assess antibiotic prescriptions and are linked to specific targets and incentives, we conducted a nationallevel survey on this topic.
Methods
We conducted an exploratory cross-sectional survey among all ESGAP (ESCMID Study Group for Antimicrobial stewardshiP) members. At the time of the survey (February 2017), ESGAP included 137 members from 23 European countries (Albania, Austria, Belgium, Bulgaria, Croatia, the Czech Republic, France, Germany, Greece, Republic of Ireland, Italy, Malta, the Netherlands, Norway, Portugal, Romania, Serbia, Slovenia, Spain, Sweden, Switzerland, Turkey and the UK) as well as 16 non-European countries (Australia, Bangladesh, Brunei, Dominican Republic, Egypt, Guatemala, Hong Kong, India, Iran, Japan, Lebanon, Pakistan, Singapore, South Africa, United Arab Emirates and the USA).
Each ESGAP member received a short questionnaire (three items, in Word format; see Document S1, available as Supplementary data at JAC Online) by e-mail, asking for: (i) availability of electronic medical records (EMRs) or any kind of computerized system that could easily produce indicators linking antibiotic prescriptions to clinical diagnoses at a national level; and (ii) the existence of indicators that assess antibiotic prescriptions with clear targets, used as prescribing incentives (e.g. payment-forperformance, accreditation, public reporting) to improve antibiotic prescribing in any setting (primary care, long-term care facilities and/or hospitals) at a national level. Only indicators linked to antibiotic prescriptions were included (not the overall antibiotic stewardship programme, or microbiology-or diagnostic-related indicators). We included public reporting only if the data were available and disclosed (with the names) at prescriber/practice level in the community or at the hospital level.
Each respondent was asked to provide links or documents detailing the indicators (Table S1) , and the lead author (C. P.) double-checked the collected data (including any inconsistency in replies coming from the respondents of the same country); respondents were also recontacted if responses were unclear.
Indicators were then categorized as either quantity metrics or quality indicators by the authors, using the following definitions: a quality indicator reflects the degree to which an antibiotic prescription is appropriate or not (i.e. the outcome is valuable by itself; e.g. prescription compliant with guidelines), whereas a quantity metric reflects the volume or the costs of antibiotic use. While this distinction may be not always 100% clear-cut, we believe it to be of value for roughly categorizing indicators.
Results
Out of 137 ESGAP members, 37 (27%) replied, coming from 20/23 (87%) European countries belonging to the ESGAP network (Albania, Austria, Belgium, Bulgaria, Croatia, France, Germany, Greece, Italy, Malta, the Netherlands, Norway, Portugal, Serbia, Slovenia, Spain, Sweden, Switzerland, Turkey and the UK) and one non-European country (India).
Computerized systems routinely linking antibiotic prescriptions to clinical diagnoses were reported for only two countries: Turkey (where such a computerized system exists in all settings) and Croatia (where it exists in primary care).
Only 6/21 (29%) countries had national indicators with both clear targets and incentives (Bulgaria, Croatia, France, the Netherlands, Norway and Portugal; Table 1 and Table S1 ). We identified a total of 21 different indicators used in these countries at the time of the study, 16 concerning inpatients (9 quality indicators and 7 quantity metrics) and 8 concerning outpatients (all quantity metrics); some indicators were used in both settings. Three types of incentives were used: financing mechanism (hospitals' financing, n " 3; or payment-for-performance in primary care, n " 4), hospitals' accreditation (n " 5) and public reporting (n " 9). Indicators targeted different aspects of antibiotic prescribing: total antibiotic use (n " 5), use of broad-spectrum antibiotics (n " 8), review of prescriptions (n " 3), compliance with guidelines (n " 4) and computerized prescribing (n " 1).
Even though it was not the purpose of the survey, some respondents reported that such indicators with both clear targets and incentives were used at a regional level in their country (e.g. Andalusia in Spain and England in the UK, where health policy is organized at a regional level); other respondents also mentioned national indicators with either a target or an incentive mechanism (e.g. Belgium and Greece; Tables S1 and S2).
Considering only quantity metrics assessing total antibiotic use, significant differences were observed regarding the different units of measurement and targets used (Table 2) . Some countries used the number of prescriptions per 1000 inhabitants per year in primary care, but set very different targets: 140 prescriptions or fewer for France (but the indicator was restricted to adults aged 16-65 years without comorbidities), 250 by 2020 for Norway and 400 by 2025 for Belgium.
Discussion
To the best of our knowledge, this is the first inventory of indicators that assess antibiotic prescriptions and are linked to clear targets and incentives, at a national level. Only few (6/21) countries had such indicators and only two countries had computerized systems that were routinely linking antibiotic prescriptions to clinical diagnoses.
Coding infectious diagnoses (requiring an antibiotic or not) in EMRs and linking these codes to antibiotic prescriptions should be promoted in all settings, since it is a prerequisite for any kind of automated measurement of quality indicators, which can measure appropriateness of prescriptions. Periodic assessment of the accuracy of the diagnostic codes is of course needed since misdiagnosis is a frequent driver of unnecessary antibiotic prescriptions, 6 and since diagnostic shift might be used by some prescribers to justify inappropriate prescriptions.
We observed wide variations between countries regarding the selected indicators, the units of measure and the chosen targets. Number of prescriptions per 1000 patients per year is possibly a better unit of measure to compare countries, as DDDs have significant shortcomings. 7 Our exploratory work includes, however, a limited number of countries (21, almost all European) and further investigation is deserved. However, we consider that sharing experiences at European level by means of a database hosted by a public agency, such as the ECDC or WHO-Europe, would be of great value. A thorough evaluation of target attainment, impact on bacterial resistance and efficacy of different incentives would be extremely informative. 8 Possible unintended consequences of decreased antibiotic prescribing should also be monitored and reported. All the above could add evidence and help setting relevant future targets. 
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